Translational Research Goes Seamless: After Creating Neurons From Patients’ Skin Cells, Cedars-Sinai-led Researchers ‘Treat’ Gene Defect in a Dish, Indicating the Therapy May Work
Although the technology has existed for just a few years, scientists increasingly use “disease in a dish” models to study genetic, molecular and cellular defects. But a team of doctors and scientists led by researchers at the Cedars-Sinai Regenerative Medicine Institute went further in a study of Lou Gehrig’s disease, a fatal disorder that attacks muscle-controlling nerve cells in the brain and spinal cord.
After using an innovative stem cell technique to create neurons in a lab dish from skin scrapings of patients who have the disorder, the researchers inserted molecules made of small stretches of genetic material, blocking the damaging effects of a defective gene and, in the process, providing “proof of concept” for a new therapeutic strategy – an important step in moving research findings into clinical trials.
The study, published Oct. 23 in Science Translational Medicine, is believed to be one of the first in which a specific form of Lou Gehrig’s disease, or amyotrophic lateral sclerosis, was replicated in a dish, analyzed and “treated,” suggesting a potential future therapy all in a single study.
“In a sense, this represents the full spectrum of what we are trying to accomplish with patient-based stem cell modeling. It gives researchers the opportunity to conduct extensive studies of a disease’s genetic and molecular makeup and develop potential treatments in the laboratory before translating them into patient trials,” said Robert H. Baloh, MD, PhD, director of Cedars-Sinai’s Neuromuscular Division in the Department of Neurology and director of the multidisciplinary ALS Program. He is the lead researcher and the article’s senior author.
Laboratory models of diseases have been made possible by a recently invented process using induced pluripotent stem cells – cells derived from a patient’s own skin samples and “sent back in time” through genetic manipulation to an embryonic state. From there, they can be made into any cell of the human body.
The cells used in the study were produced by the Induced Pluripotent Stem Cell Core Facility of Cedars-Sinai’s Regenerative Medicine Institute. Dhruv Sareen, PhD, director of the iPSC facility and a faculty research scientist with the Department of Biomedical Sciences, is the article’s first author and one of several institute researchers who participated in the study.
“In these studies, we turned skin cells of patients who have ALS into motor neurons that retained the genetic defects of the disease,” Baloh said. “We focused on a gene, C9ORF72, that two years ago was found to be the most common cause of familial ALS and frontotemporal lobar degeneration, and even causes some cases of Alzheimer’s and Parkinson’s disease. What we needed to know, however, was how the defect triggered the disease so we could find a way to treat it.”
Frontotemporal lobar degeneration is a brain disorder that typically leads to dementia and sometimes occurs in tandem with ALS.
The researchers found that the genetic defect of C9ORF72 may cause disease because it changes the structure of RNA coming from the gene, creating an abnormal buildup of a repeated set of nucleotides, the basic components of RNA.
“We think this buildup of thousands of copies of the repeated sequence GGGGCC in the nucleus of patients’ cells may become “toxic” by altering the normal behavior of other genes in motor neurons,” Baloh said. “Because our studies supported the toxic RNA mechanism theory, we used two small segments of genetic material called antisense oligonucleotides – ASOs – to block the buildup and degrade the toxic RNA. One ASO knocked down overall C9ORF72 levels. The other knocked down the toxic RNA coming from the gene without suppressing overall gene expression levels. The absence of such potentially toxic RNA, and no evidence of detrimental effect on the motor neurons, provides a strong basis for using this strategy to treat patients suffering from these diseases.”
Researchers from another institution recently led a phase one trial of a similar ASO strategy to treat ALS caused by a different genetic mutation and reportedly uncovered no safety issues.
Clive Svendsen, PhD, director of the Regenerative Medicine Institute and one of the article’s authors, has studied ALS for more than a decade. “ALS may be the cruelest, most severe neurological disease, but I believe the stem cell approach used in this collaborative effort holds the key to unlocking the mysteries of this and other devastating disorders. Within the Regenerative Medicine Institute, we are exploring several other stem cell-based strategies in search of treatments and cures,” he said, adding that ALS affects 30,000 to 50,000 people in the U.S., but unlike other neurodegenerative diseases, it is almost always fatal, usually within three to five years.
Go deeper with Bing News on:
- Als officially announce extension for Eugene Lewison February 4, 2020 at 7:26 am
MONTREAL – The Montreal Alouettes announced on Tuesday that the club has signed American receiver Eugene Lewis to a new one-year-deal. Lewis was Vernon Adams Jr.’s favourite target in 2019, catching ...
- The upper cervical spinal cord in ALS assessed by cross-sectional and longitudinal 3T MRIon February 4, 2020 at 2:35 am
The upper cervical spinal cord is measured in a large longitudinal amyotrophic lateral sclerosis (ALS) cohort to evaluate its role as a biomarker. Specifically, the cervical spinal cord´s ...
- Broken Arrow man fighting to get congress to approve easier access to ALS treatmenton February 3, 2020 at 9:04 pm
A Broken Arrow man living with ALS is asking for an Executive Order from President Trump to grant easier access to treatment not yet FDA approved but already showing success. Last year, FOX23 ...
- Als sign bruising RB Wilder to fill void left by Stanback's departureon January 31, 2020 at 8:52 am
It’s no secret the Alouettes were in the market for a running back after William Stanback signed with the Las Vegas Raiders. And, knowing James Wilder was available after his early release by the ...
- Action News Troubleshooters gets healthcare help for ALS patienton January 30, 2020 at 9:11 pm
And that is exactly why the Troubleshooters are here to help. Gregg Lipschultz's body is failing but his mind is as sharp as ever. That is the painful reality of ALS, also known as Lou Gehrig's ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Lou Gehrig’s disease
- Westerville North Roundup: Matt Simmons' fight with ALS sparks fundraisingon February 4, 2020 at 12:32 pm
The Warriors placed a bucket at the gate during their two home dual matches this season to raise money to aid research of the progressive nervous system disease that weakens muscles and limits ...
- Hamburg Township Trustee Jim Neilson dies after battle with Lou Gehrig's Diseaseon February 3, 2020 at 2:42 pm
Hamburg Township Trustee Jim Neilson dies after battle with Lou Gehrig's Disease After battling ALS for approximately a year, former Hamburg Township Clerk Jim Neilson died Monday. Check out this ...
- Disabled Children Losing Medicaid Coverage, Families Desperate for Helpon February 3, 2020 at 9:49 am
Lindsey Eubanks is the mother of Lucas Eubanks, 3, who suffers from a juvenile form of Lou Gehrig's disease. She worries that the bill does not go far enough. Mississippi families making more than $78 ...
- Blizzard Tour sets record for ALSon February 3, 2020 at 7:31 am
The 21st annual Black Woods Blizzard Tour netted a record $1.36 million for those battling Lou Gehrig's disease, organizers said. The three-day snowmobile ride concluded Saturday with a banquet at ...
- Family, friends remember longtime artist, teacheron January 31, 2020 at 12:14 pm
resident said with a laugh. The quick-witted Blumberg, who was also an accomplished artist, died Dec. 9 at the age of 83 after a short battle with Lou Gehrig’s disease. “My mom was my best friend,” ...